（股份代號：2291） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 LEPU SCIENTECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.* 樂普心泰醫療科技（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 董事會會議通告 樂普心泰醫療科技（上海）股份有限公司（「本公司」）董事（「董事」）會（「董事會」） 謹此宣佈，本公司將於2025年8月22日（星期五）舉行董事會會議，藉以（其中包 括）考慮及批准本公司及其附屬公司截至2025年6月30日止六個月的未經審核中期 業績及其發佈，並考慮建議派發中期股息（如有）。 * 本公司註冊為香港法例第622章《公司條例》所定義的非香港公司，以其中文名稱及英文名 稱「LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.」註冊。 承董事會命 樂普心泰醫療科技（上海）股份有限公司 陳娟女士 董事長兼執行董事 中 ...

FF301 致：香港交易及結算所有限公司 公司名稱: 樂普心泰醫療科技（上海）股份有限公司 (「本公司」) 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02291 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 346,749,997 | RMB | | 1 RMB | | 346,749,997 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 346,749,997 | RMB | | 1 RMB | | 346,749,997 | 本月底法定/註冊股本總額： RMB 346,749,997 備註： 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2 ...

[Company Announcement: Proposed Appointment of Supervisor and Supplemental Announcement Regarding Annual Reports](index=1&type=section&id=%E5%85%AC%E5%8F%B8%E5%85%AC%E5%91%8A%EF%BC%9A%E5%BB%BA%E8%AD%B0%E5%A7%94%E4%BB%BB%E7%9B%A3%E4%BA%8B%E5%8F%8A%E6%9C%89%E9%97%9C%E5%B9%B4%E5%A0%B1%E4%B9%8B%E8%A3%9C%E5%85%85%E5%85%AC%E5%91%8A) This announcement details the proposed appointment of a new supervisor and clarifies supervisor remuneration in annual reports [Proposed Appointment of Supervisor](index=1&type=section&id=%E5%BB%BA%E8%AD%B0%E5%A7%94%E4%BB%BB%E7%9B%A3%E4%BA%8B) The company proposes Ms. Wang Yong as shareholder representative supervisor and chairperson, pending shareholder approval - The company's board of supervisors recommends appointing Ms. Wang Yong as a supervisor and chairperson of the second board of supervisors[3](index=3&type=chunk) - This appointment is subject to approval by an ordinary resolution at the general meeting of shareholders[3](index=3&type=chunk)[8](index=8&type=chunk) - As a shareholder representative supervisor, Ms. Wang will not receive any remuneration from the company[7](index=7&type=chunk) [Supervisor Candidate Background: Ms. Wang Yong](index=1&type=section&id=%E7%9B%A3%E4%BA%8B%E5%80%99%E9%81%B8%E4%BA%BA%E7%9A%84%E8%83%8C%E6%99%AF) Ms. Wang Yong, 52, CFO of Lepu Medical, possesses CPA qualifications and audit experience Key Background Information | Item | Content | | :--- | :--- | | Age | 52 | | Nationality | China | | Current Key Positions | CFO, Senior Deputy General Manager at Lepu Medical (Controlling Shareholder, 300003.SZ) | | Past Key Experience | Senior Audit Manager, Audit Department, PwC Zhong Tian CPAs Beijing Branch (1996-2007) | | Professional Qualifications | Certified Public Accountant (obtained 2001) | Shareholding Information | Company Held | Capacity | Shares/Percentage | | :--- | :--- | :--- | | The Company | Via Employee Stock Ownership Platform | 147,221 shares (approx. 0.04%) | | Lepu Medical | Beneficial Owner | 191,700 shares (approx. 0.01%) | | Beijing Lepu Diagnostics | Via Employee Stock Ownership Platform | 383,955 shares (approx. 0.10%) | - Ms. Wang holds director or supervisor positions in several affiliated or non-affiliated companies, including Sichuan Ruijian Medical, Shanghai Lepu Yunzhi, and Sino-American Huashitong[4](index=4&type=chunk) [Supplemental Announcement Regarding Annual Reports](index=3&type=section&id=%E6%9C%89%E9%97%9C%E5%B9%B4%E5%A0%B1%E4%B9%8B%E8%A3%9C%E5%85%85%E5%85%AC%E5%91%8A) The company clarifies that total remuneration paid to all supervisors for fiscal years 2022-2024 was zero - This announcement provides supplementary information for the company's 2022, 2023, and 2024 annual reports[9](index=9&type=chunk) Total Remuneration Paid to All Supervisors | Fiscal Year | Total Remuneration Paid to All Supervisors | | :--- | :--- | | 2022 | Zero | | 2023 | Zero | | 2024 | Zero | - The disclosed total remuneration of zero covers all items, including fees, basic salary, housing allowances, in-kind benefits, and bonuses[9](index=9&type=chunk)

Group 1 - The medical and pharmaceutical sector continues to perform strongly, with the Hong Kong medical ETF (159366) rising over 2% in early trading, marking a three-day increase [1] - Key stocks such as Kelaiying, Micron Medical, and Zhaoyan Pharmaceutical saw significant gains of 5.90%, 5.47%, and 4.73% respectively, contributing to a cumulative increase of 6.32% in the ETF over the past week [1] - A major policy announcement from the Central Committee and the State Council aims to improve public welfare and healthcare, including the establishment of a drug catalog adjustment mechanism and the promotion of quality healthcare resource sharing [1] Group 2 - Dongwu Securities highlights three factors that suggest 2025 will be a pivotal year for innovative drugs, including the orderly rollout of significant business development (BD) deals, expected profitability for more companies by 2026, and an improving domestic environment for innovative drugs [2] - The Chinese innovative drug market is poised for rapid growth, supported by favorable policies and international expansion, making it a highly promising sub-sector within the pharmaceutical industry [2] - The Hong Kong medical ETF (159366) focuses on unique medical segment leaders, including internet healthcare, CXO, and medical devices, and operates as a pure Hong Kong Stock Connect ETF with T+0 trading support [2]

Core Viewpoint - The article highlights the successful commercialization and clinical application of the ScienCrown transcatheter aortic valve replacement (TAVR) system developed by Lepu Medical Technology, marking a significant advancement in the treatment of aortic stenosis patients in China [2][5][10]. Company Overview - Lepu Medical Technology (Shanghai) Co., Ltd. is a leading innovator in the field of interventional medical devices for structural heart diseases, supported by the Shanghai Biomedical Investment Fund. The company went public on November 8, 2022, on the Hong Kong Stock Exchange under the stock code 02291.HK [17]. - The company focuses on the research, development, production, and marketing of interventional medical devices, with over 40 products listed and in development, covering congenital heart disease, stroke prevention, and valve treatment solutions [17]. Product Introduction - The ScienCrown TAVR system is the world's first and only self-expanding short valve product with balloon-expandable advantages, designed to address existing challenges in TAVR procedures [4][12]. - The product features 100% full release and retrieval capabilities, dual access routes, and innovative designs that significantly enhance clinical practice [4][12][15]. Clinical Application - The first commercial implantations of the ScienCrown valve have been successfully conducted in multiple clinical centers across China, demonstrating its effectiveness and safety [5][7]. - Clinical trial results indicate a procedural success rate of approximately 99.2% and a device success rate of about 98.4%, with low rates of paravalvular leak and no severe leaks reported [7][10]. Market Context - Aortic valve disease, particularly aortic stenosis (AS), is a common cardiovascular issue, especially among the elderly, with a prevalence of approximately 11.5% in patients over 60 years old [8][10]. - The number of patients with aortic stenosis and aortic regurgitation in China is projected to reach 9.3 million by 2025, with a compound annual growth rate of 2.6% from 2022 to 2025 [10].

Group 1 - The Hong Kong stock market showed strength on April 25, with the Hang Seng Healthcare Index initially rising before retreating, and the Hang Seng Healthcare Index ETF (159557) increasing by over 1%, leading in gains among similar ETFs, with a premium trading rate of 0.61% [1] - Key stocks in the healthcare sector included Xintai Medical, which rose over 6%, Jingtai Holdings, which increased over 5%, and iFlytek Medical Technology, which gained over 4% [1] - A new policy from the Ministry of Industry and Information Technology and six other departments was announced on April 24, outlining the "Implementation Plan for the Digital Transformation of the Pharmaceutical Industry (2025-2030)", with significant goals set for 2027 and 2030 regarding technological advancements and digital transformation in the pharmaceutical sector [1] Group 2 - Guolian Minsheng Securities identified two core investment themes for the pharmaceutical sector in 2025: 1) High-quality innovative drugs going overseas, as domestic IND products are well-positioned for international markets; 2) Valuation recovery of left-side assets, focusing on sectors like CXO, consumer healthcare, and pharmacies that have seen significant pullbacks [2] - Huaxin Securities noted that the market is entering a period of consolidation, with potential challenges from simultaneous withdrawals of southbound and foreign capital, but maintains a bullish outlook for the medium term, emphasizing opportunities in the core technology sector and the long-term potential of the innovative drug industry post-policy adjustments [2]

Group 1 - The Hang Seng Index opened with a gain of 2.4% [1] - The Hang Seng Tech Index opened with a gain of 3.5% [1] - HeartTech Medical (02291.HK) surged 8.28% after resuming trading [1] Group 2 - Pop Mart (09992.HK) opened with a gain of 4.6% and announced a year-on-year revenue growth of 165%-170% for Q1 2025 [1]

Core Viewpoint - The investment logic of "mother holding child" is gaining attention among fund managers as they seek undervalued stocks in the Hong Kong market, particularly in the pharmaceutical sector [1][3]. Group 1: Market Trends - Following a significant surge in the stock of Boan Biotechnology, a subsidiary of Green Leaf Pharmaceutical, which rose by 66%, another subsidiary, HeartTech Medical, saw a 47% increase, indicating a trend of "smoking stocks" in the Hong Kong pharmaceutical sector [2][3]. - The influx of new capital into the Hong Kong market is evident as public funds are shifting their focus from U.S. medical device stocks to A-share and Hong Kong pharmaceutical assets [2][5]. Group 2: Fund Manager Strategies - Fund managers are increasingly adopting a strategy of directly holding shares in parent companies rather than their subsidiaries, reflecting a preference for companies with stronger business fundamentals and competitive advantages [3][4]. - A notable shift in a QDII fund's portfolio was observed, where the allocation to A-shares and Hong Kong stocks increased significantly, indicating a strategic pivot away from U.S. stocks [6]. Group 3: Industry Performance - HeartTech Medical reported a total revenue of 472 million yuan, a year-on-year increase of 44.4%, and a net profit of 246 million yuan, up 62.22%, showcasing strong performance in the sector [4]. - The pharmaceutical sector is expected to show relative gains by 2025, driven by new industry trends and a recovery from historically low valuation levels [8][9]. Group 4: Policy and Innovation - Recent favorable policies for the pharmaceutical industry, including support for drug and medical device innovation, are expected to enhance the growth prospects for innovative drug companies [9]. - The increasing global presence of Chinese innovative drug companies is highlighted by their significant contributions to international academic conferences, indicating a robust growth trajectory [9].

Financial Performance - The company reported a consolidated revenue of HK$1.2 billion for the fiscal year 2024, representing a year-on-year increase of 15%[1]. - Lepu Medical Technology reported a revenue increase of 15% year-over-year for the last fiscal year, reaching RMB 1.2 billion[10]. - For the year ended December 31, 2024, the Company achieved revenue of RMB471.6 million, representing a year-on-year increase of 44.4% from 2023[57]. - Revenue from CHD occluder products grew by 6.8% from RMB230.2 million in 2023 to RMB245.9 million in 2024, representing 70.4% and 52.2% of total revenue, respectively[106]. - Revenue from pathway products increased by 22.1% from RMB66.5 million in 2023 to RMB81.3 million in 2024, accounting for 20.4% and 17.2% of total revenue, respectively[107]. - Revenue from PFO and LAA occluder products surged by 396.6% from RMB29.0 million in 2023 to RMB143.9 million in 2024, representing 8.9% and 30.5% of total revenue, respectively[110]. - Net profit attributable to shareholders of the parent company increased by 62.2% from RMB151.4 million for the year ended December 31, 2023, to RMB245.6 million for the year ended December 31, 2024[26]. - The company achieved a net profit margin of 20%, reflecting strong operational efficiency and cost management[10]. User Growth and Market Expansion - User data showed a growth in active users by 25%, reaching a total of 500,000 users by the end of the fiscal year[1]. - User data indicated a 25% growth in the number of active users of Lepu's medical devices, totaling 500,000 users[10]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[1]. - Lepu Medical plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by 2025[10]. Research and Development - Investment in R&D increased by 30%, focusing on innovative medical technologies and product enhancements[1]. - The company is investing RMB 200 million in R&D for new medical technologies, including advancements in transcatheter valve replacement systems[10]. - The company launched seven new products in the past year, enhancing its product pipeline in the structural heart disease sector[35]. - The company is actively working on new product development, including biodegradable LAA delivery systems, which are in the preparation stage for registration materials[53]. Product Development and Innovation - The company introduced two new products in the cardiovascular segment, which are anticipated to contribute an additional HK$200 million in revenue next year[1]. - Lepu Medical's new product line, including the TMVR system, is expected to launch in Q3 2024, aiming to capture a significant share of the minimally invasive surgery market[10]. - The company has successfully commercialized multiple occluder products, including MemoPart® ASD occluder (double-rivet), MemoPart® VSD occluder (double-rivet), and MemoPart® PDA occluder (double-rivet)[47]. - The company is preparing for the initiation of overseas clinical trials for MemoSorb® fully-degradable occluder systems[47]. Sustainability Initiatives - Future guidance includes a commitment to sustainability initiatives, with a target of reducing carbon emissions by 25% over the next five years[1]. - Lepu Medical is committed to sustainability initiatives, aiming to reduce its carbon footprint by 15% over the next three years[10]. Financial Management and Cost Control - The gross profit margin improved to 60%, up from 55% in the previous year, due to cost optimization measures[1]. - The company aims to reduce operational costs by 15% through efficiency improvements and automation[1]. - Operating costs rose by 26.9% from RMB37.5 million in 2023 to RMB47.6 million in 2024[115]. - Labor costs rose by 39.7% from RMB10.9 million in 2023 to RMB15.2 million in 2024, driven by increased output and sales volume[120]. Leadership and Management - Ms. Chen has been serving as the Executive Director and General Manager since January 29, 2021, and has been with the Group since December 2011[182]. - Ms. Zhang has been a Director since January 29, 2021, and was appointed as Deputy General Manager and Chief Technology Officer on May 28, 2021[184]. - The Group's management team has a diverse background in both engineering and business, enhancing its strategic decision-making[190]. - The leadership team has a strong track record in both domestic and international markets, positioning the company for future growth[190].

Financial Performance - Revenue increased by 44.4% from RMB 326.6 million for the year ended December 31, 2023, to RMB 471.6 million for the year ended December 31, 2024[3]. - Gross profit rose by 46.7% from RMB 289.1 million for the year ended December 31, 2023, to RMB 424.0 million for the year ended December 31, 2024[3]. - Net profit attributable to shareholders increased by 62.2% from RMB 151.4 million for the year ended December 31, 2023, to RMB 245.6 million for the year ended December 31, 2024[3]. - The net cash flow from operating activities was RMB 222.5 million, up 35.5% from the previous year[8]. - The total assets of the group amounted to RMB 2,083.0 million, reflecting a 4.8% increase from the beginning of the year[8]. - The net assets of the group were RMB 1,997.0 million, which is a 3.7% increase from the beginning of the year[8]. - Operating profit for 2024 was RMB 286,135,584.69, up 65.9% from RMB 172,327,097.00 in 2023[69]. - The total comprehensive income attributable to the parent company for the year ended December 31, 2024, was RMB 245,559,893.33, compared to RMB 151,378,805.98 for the previous year, representing an increase of approximately 62%[72]. - Basic and diluted earnings per share for the year were both RMB 0.71, up from RMB 0.44 in the previous year, indicating a growth of approximately 61.36%[72]. Research and Development - Research and development expenses decreased by 6.6% from RMB 62.1 million for the year ended December 31, 2023, to RMB 58.0 million for the year ended December 31, 2024[3]. - The company has a total of 29 commercialized products and 28 products in various stages of research and development[5]. - The company is focusing on biodegradable medical devices and exploring advanced fields such as cardiac mechanical circulatory support[5]. - The company is engaged in the research and development of biological valves for heart disease treatment, indicating ongoing innovation in its product offerings[73]. - The company is focusing on the development of vascular closure devices, with significant market potential in China as no products have been approved yet[22]. Product Development and Market Strategy - The company aims to provide safe, efficient, innovative, and comprehensive medical solutions in the cardiac intervention device industry[5]. - The company has 4 products under registration review and preparation, with several others in clinical trials[6]. - The biodegradable oval foramen occluder has generated sales revenue close to one-third of the total revenue, highlighting its market success[11]. - Two innovative products targeting aortic dissection and abdominal aortic aneurysm are entering clinical trials, representing significant advancements in the company's product offerings[12]. - The company is developing a transcatheter aortic valve system for patients with isolated aortic regurgitation, with clinical trials planned to start by the end of 2025 after successful animal testing[13]. - The company has entered the mechanical circulatory support (MCS) device market, with various products in preclinical and clinical testing stages, aiming to provide optimal medical solutions for patients[15]. - The company aims to continue developing innovative medical solutions for structural heart disease, focusing on core technologies and product development[18]. - The company is positioned to leverage its first-mover advantage and superior product characteristics to capture significant market potential in the high-growth, low-penetration domestic market[19]. Financial Management and Expenses - Operating costs rose by 26.9% from RMB 37.5 million for the year ending December 31, 2023, to RMB 47.6 million for the year ending December 31, 2024[31]. - Sales expenses surged by 56.8% from RMB 45.4 million for the year ending December 31, 2023, to RMB 71.1 million for the year ending December 31, 2024[38]. - Management expenses decreased by 15.4% from RMB 42.1 million for the year ending December 31, 2023, to RMB 35.6 million for the year ending December 31, 2024[39]. - Financial expenses improved from RMB -8.7 million for the year ending December 31, 2023, to RMB -23.9 million for the year ending December 31, 2024, reflecting an increase in interest income[41]. - Income tax expense increased by 87.1% from RMB 21.7 million for the year ended December 31, 2023, to RMB 40.5 million for the year ending December 31, 2024, primarily due to increased taxable income from business performance growth[43]. Market Presence and Future Outlook - The company plans to enhance its marketing team and expand its sales network in China to improve brand recognition and service capabilities[23]. - The company aims to increase the market penetration of existing products and establish a good reputation for Chinese brands in the global market[24]. - The global market for mechanical circulatory support (MCS) is expected to grow at a compound annual growth rate of over 10%, reaching approximately USD 3.4 billion by 2025[21]. - The company plans to fully utilize the net proceeds from the global offering by December 31, 2027, subject to business needs and market conditions[115]. Corporate Governance and Compliance - The company has adopted the Corporate Governance Code as its own governance code and has complied with its provisions during the reporting period, with some deviations noted[117]. - The company confirmed compliance with the Standard Code for securities trading by directors and supervisors during the reporting period[118]. - The Audit Committee, consisting of two independent non-executive directors and one non-executive director, reviewed the consolidated financial statements for the year ending December 31, 2024[120].